OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← Ovarian, Fallopian Tube & Primary Peritoneal Cancer Overview

Ovarian, Fallopian Tube & Primary Peritoneal Cancer — 342 Curated Clinical Trials

Registry Snapshot: 2026-10-23 · Table SHA-256: e688f6c7c7c155c6

NCT IdentifierTitle & SponsorPhase / Status
NCT00539162Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
M.D. Anderson Cancer Center
NA
RECRUITING
NCT01174121Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
PHASE2
RECRUITING
NCT01558544Cryopreservation of Ovarian Tissue
Weill Medical College of Cornell University
NA
RECRUITING
NCT02830724Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
PHASE1|PHASE2
RECRUITING
NCT03011684Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
University of California, San Francisco
PHASE3
RECRUITING
NCT03067181Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Children's Oncology Group
PHASE3
RECRUITING
NCT03412877Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
PHASE2
RECRUITING
NCT03544983Genetic Education in BRCA Families
Georgetown University
NA
ENROLLING_BY_INVITATION
NCT03564340Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
PHASE1|PHASE2
RECRUITING
NCT03604315Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
PHASE1
RECRUITING
NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Immatics US, Inc.
PHASE1|PHASE2
RECRUITING
NCT03854110A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
Persevere Therapeutics Inc.
PHASE1
RECRUITING
NCT03878849Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Allarity Therapeutics
PHASE2
RECRUITING
NCT03968406Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
PHASE1
RECRUITING
NCT04038619Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
PHASE1
RECRUITING
NCT04055649ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Ira Winer
PHASE2
RECRUITING
NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
PHASE1|PHASE2
RECRUITING
NCT04107077Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
University of Chicago
PHASE2
RECRUITING
NCT04196257BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings, Inc.
PHASE1
RECRUITING
NCT04251052A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NRG Oncology
NA
RECRUITING
NCT04282044Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
PHASE1
RECRUITING
NCT04294927TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
University Medical Center Nijmegen
NA
RECRUITING
NCT04300556A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
PHASE1|PHASE2
RECRUITING
NCT04329494PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
PHASE1
RECRUITING
NCT04389632A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
PHASE1
RECRUITING
NCT04429542Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
PHASE1
RECRUITING
NCT04469764Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
PHASE2
RECRUITING
NCT04473833Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
John R van Nagell
NA
RECRUITING
NCT04494945Identifying and Caring for Individuals With Inherited Cancer Syndrome
OHSU Knight Cancer Institute
NA
RECRUITING
NCT04503265A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AtlasMedx, Incorporated
PHASE1|PHASE2
RECRUITING
NCT04516447A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
PHASE1
RECRUITING
NCT04520139Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
University of California, Irvine
PHASE1|PHASE2
RECRUITING
NCT04575935Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
PHASE3
RECRUITING
NCT04585750The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PHASE1|PHASE2
RECRUITING
NCT04585958Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
PHASE1
RECRUITING
NCT04590326A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
PHASE1|PHASE2
RECRUITING
NCT04606914Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
University of Alabama at Birmingham
PHASE2
RECRUITING
NCT04633239Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
PHASE1
RECRUITING
NCT04641247A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
PHASE2
RECRUITING
NCT04657068A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
PHASE1|PHASE2
RECRUITING
NCT04701645Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
PHASE1
RECRUITING
NCT04751435Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Memorial Sloan Kettering Cancer Center
NA
RECRUITING
NCT04752826BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
BioInvent International AB
PHASE1|PHASE2
RECRUITING
NCT04779554Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Prakash Pandalai
PHASE2
RECRUITING
NCT04804007Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Nabil Adra
PHASE2
RECRUITING
NCT04847063Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Cancer Institute (NCI)
PHASE1
RECRUITING
NCT04851119Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
PHASE1|PHASE2
RECRUITING
NCT04858009Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
PHASE2
ACTIVE_NOT_RECRUITING
NCT04890613Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Senhwa Biosciences, Inc.
PHASE1
RECRUITING
NCT04895709A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
PHASE1|PHASE2
RECRUITING
NCT04907643Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
NA
RECRUITING
NCT04918186Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Canadian Cancer Trials Group
PHASE2
RECRUITING
NCT04919629APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
PHASE2
RECRUITING
NCT04997096Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Dana-Farber Cancer Institute
NA
RECRUITING
NCT05000294Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
PHASE1|PHASE2
RECRUITING
NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
PHASE1
RECRUITING
NCT05039801IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
PHASE1
RECRUITING
NCT05071937ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
PHASE2
RECRUITING
NCT05086692A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics, Inc.
PHASE1|PHASE2
RECRUITING
NCT05092373Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
PHASE1
RECRUITING
NCT05103683First in Human Study of TORL-1-23 in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
PHASE1
RECRUITING
NCT05107674A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
PHASE1
RECRUITING
NCT05112601Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
National Cancer Institute (NCI)
PHASE2
RECRUITING
NCT05113368Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Sarah K. Lynam MD
PHASE2
RECRUITING
NCT05123482A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
PHASE1|PHASE2
RECRUITING
NCT05123807Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
M.D. Anderson Cancer Center
PHASE2
RECRUITING
NCT05128825A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
PHASE2
RECRUITING
NCT05130606CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Georgetown University
NA
RECRUITING
NCT05225363Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
City of Hope Medical Center
PHASE1
RECRUITING
NCT05225428Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NA
COMPLETED
NCT05227326AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
PHASE1
RECRUITING
NCT05231122Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
PHASE2
RECRUITING
NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
PHASE3
RECRUITING
NCT05287451Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
M.D. Anderson Cancer Center
NA
RECRUITING
NCT05297734Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
NA
RECRUITING
NCT05316129Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
PHASE1
RECRUITING
NCT05349227Comprehensive Outcomes for After Cancer Health
Pack Health
NA
RECRUITING
NCT05377996A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Day One Biopharmaceuticals, Inc.
PHASE1|PHASE2
RECRUITING
NCT05417594Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
AstraZeneca
PHASE1|PHASE2
RECRUITING
NCT05429970A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Memorial Sloan Kettering Cancer Center
NA
RECRUITING
NCT05467891Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Oana Danciu
PHASE2
RECRUITING
NCT05479045A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Georgetown University
PHASE2
WITHDRAWN
NCT05489211Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
PHASE2
RECRUITING
NCT05503797A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
PHASE2
RECRUITING
NCT05512208A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
University of Oklahoma
PHASE2
RECRUITING
NCT05538091Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Ronald Buckanovich
PHASE2
RECRUITING
NCT05564377Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
PHASE2
RECRUITING
NCT05568680SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
PHASE1
RECRUITING
NCT05579366Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
PHASE1|PHASE2
RECRUITING
NCT05610735Combination Therapy for Recurrent Ovarian Cancer
Sham Sunder Kakar
PHASE1|PHASE2
RECRUITING
NCT05636111Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
M.D. Anderson Cancer Center
PHASE1
RECRUITING
NCT05645536Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
PHASE3
ENROLLING_BY_INVITATION
NCT05649072Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
M.D. Anderson Cancer Center
NA
RECRUITING
NCT05659381Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
GOG Foundation
PHASE3
RECRUITING
NCT05684965XTX301 in Patients With Advanced Solid Tumors
Xilio Development, Inc.
PHASE1|PHASE2
RECRUITING
NCT05721976With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
University of Miami Sylvester Comprehensive Cancer Center
NA
RECRUITING
NCT05733000CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
PHASE2
RECRUITING
NCT05735080Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
PHASE1|PHASE2
RECRUITING
NCT05739981Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Imunon
PHASE1|PHASE2
RECRUITING
NCT05743517Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Northwestern University
NA
ACTIVE_NOT_RECRUITING
NCT05746897A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
PHASE1
RECRUITING
NCT05752448Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
Baylor College of Medicine
NA
RECRUITING
NCT05753306Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
PHASE2
RECRUITING
NCT05761561Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer
Yale University
NA
RECRUITING
NCT05768139First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Eli Lilly and Company
PHASE1|PHASE2
RECRUITING
NCT05794659Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
Aston Sci. Inc.
PHASE2
NOT_YET_RECRUITING
NCT05797168Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
AstraZeneca
PHASE1|PHASE2
RECRUITING
NCT05804370Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NX Development Corp
PHASE3
RECRUITING
NCT05824975A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
PHASE1|PHASE2
RECRUITING
NCT05844865Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis
University of California, Irvine
NA
RECRUITING
NCT05867251Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
PHASE1|PHASE2
RECRUITING
NCT05877599A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
PHASE1
RECRUITING
NCT05879926Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NRG Oncology
PHASE3
RECRUITING
NCT05887609An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
PHASE2
RECRUITING
NCT05902988A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics, Inc.
PHASE1|PHASE2
RECRUITING
NCT05910294A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NA
RECRUITING
NCT05914116A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
PHASE1|PHASE2
RECRUITING
NCT05921149Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
Endeavor Health
NA
NOT_YET_RECRUITING
NCT05932862A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
PHASE1
RECRUITING
NCT05941507A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
PHASE1|PHASE2
RECRUITING
NCT05942300CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Lan Coffman
PHASE1
RECRUITING
NCT05950464Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
National Cancer Institute (NCI)
PHASE1
RECRUITING
NCT05952453Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
University of Alabama at Birmingham
PHASE2
RECRUITING
NCT05969860At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
PHASE2
RECRUITING
NCT05983276Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University
PHASE2
RECRUITING
NCT05983432Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
PHASE1
RECRUITING
NCT05985655Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
PHASE1|PHASE2
RECRUITING
NCT05990426Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Northwestern University
NA
RECRUITING
NCT05998135Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Emory University
PHASE2
RECRUITING
NCT06014502Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis
PHASE1
RECRUITING
NCT06036810Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
M.D. Anderson Cancer Center
NA
RECRUITING
NCT06040970Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Icahn School of Medicine at Mount Sinai
PHASE1|PHASE2
RECRUITING
NCT06051695A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
PHASE1|PHASE2
RECRUITING
NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
M.D. Anderson Cancer Center
PHASE1|PHASE2
RECRUITING
NCT06072781A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem, Inc.
PHASE3
RECRUITING
NCT06083844Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
PHASE2
RECRUITING
NCT06084481Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
PHASE1
RECRUITING
NCT06084780Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
Case Comprehensive Cancer Center
PHASE2
NOT_YET_RECRUITING
NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
PHASE1|PHASE2
RECRUITING
NCT06161025A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
PHASE2|PHASE3
RECRUITING
NCT06172478A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
PHASE2
RECRUITING
NCT06178614A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
PHASE1
RECRUITING
NCT06188520A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
AstraZeneca
PHASE1|PHASE2
RECRUITING
NCT06220864SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
PHASE1
RECRUITING
NCT06234423A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
OnCusp Therapeutics, Inc.
PHASE1
RECRUITING
NCT06242470A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
PHASE1
RECRUITING
NCT06253130A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Eikon Therapeutics
PHASE1|PHASE2
RECRUITING
NCT06268665Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
University of California, Davis
PHASE2
RECRUITING
NCT06270706A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
PHASE1
RECRUITING
NCT06276491Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
PHASE1
RECRUITING
NCT06290193Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
PHASE2
RECRUITING
NCT06293898Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
PHASE1
RECRUITING
NCT06297525Study of STP938 (Dencatistat) in Advanced Solid Tumours
Step Pharma, SAS
PHASE1
RECRUITING
NCT06303505FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Gilead Sciences
PHASE1|PHASE2
RECRUITING
NCT06305299Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
PHASE1
RECRUITING
NCT06312124A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NA
RECRUITING
NCT06321484Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
PHASE1
RECRUITING
NCT06330064A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
PHASE1|PHASE2
RECRUITING
NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
PhotonPharma, Inc.
PHASE1
RECRUITING
NCT06386146JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Jacobio Pharmaceuticals Co., Ltd.
PHASE1|PHASE2
RECRUITING
NCT06386887Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
Case Comprehensive Cancer Center
NA
RECRUITING
NCT06394804A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Memorial Sloan Kettering Cancer Center
PHASE2
RECRUITING
NCT06395519A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics, Inc.
PHASE1|PHASE2
RECRUITING
NCT06400472A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
PHASE1
RECRUITING
NCT06412120Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
PHASE4
RECRUITING
NCT06422455Access to Genetic Testing in Underserved Patients With Cancer
University of Southern California
NA
RECRUITING
NCT06430541Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
University of Colorado, Denver
PHASE1
RECRUITING
NCT06431594A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
GlaxoSmithKline
PHASE1
RECRUITING
NCT06451497This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
PHASE1
RECRUITING
NCT06458712Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Duke Street Bio Ltd
PHASE1
RECRUITING
NCT06465069A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
PHASE1
RECRUITING
NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
PHASE1
RECRUITING
NCT06476808A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Bristol-Myers Squibb
PHASE1
RECRUITING
NCT06483048MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
PHASE1
RECRUITING
NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
PHASE2
RECRUITING
NCT0650314618F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
PHASE2
RECRUITING
NCT06504147A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Oncoinvent Solutions AS
PHASE2
RECRUITING
NCT06511037PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
University of California, Irvine
EARLY_PHASE1
RECRUITING
NCT06513962Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Children's Oncology Group
PHASE3
RECRUITING
NCT06515613A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
PHASE1
RECRUITING
NCT06518746Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation
University of Colorado, Denver
NA
RECRUITING
NCT06526819SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
PHASE1|PHASE2
RECRUITING
NCT06543537Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Dana-Farber Cancer Institute
NA
RECRUITING
NCT06545604Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
M.D. Anderson Cancer Center
NA
RECRUITING
NCT06545942Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
PHASE1
RECRUITING
NCT06580002Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
PHASE2
RECRUITING
NCT06580314Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
PHASE3
RECRUITING
NCT06582017Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
PHASE1
RECRUITING
NCT06586957A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
PHASE1
RECRUITING
NCT06617923Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PHASE2
RECRUITING
NCT06620029BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
BioMimetix JV, LLC
PHASE1|PHASE2
NOT_YET_RECRUITING
NCT06623396A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
PHASE1
RECRUITING
NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Mayo Clinic
PHASE2
RECRUITING
NCT06646627Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
Stanford University
PHASE1
RECRUITING
NCT06677190Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
PHASE2
RECRUITING
NCT06682988A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
AbbVie
PHASE2
RECRUITING
NCT06690775CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC
PHASE2
RECRUITING
NCT06695845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
PHASE2
RECRUITING
NCT06710288A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
ImmunityBio, Inc.
PHASE2
RECRUITING
NCT06710548REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Dana-Farber Cancer Institute
NA
RECRUITING
NCT06710756Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
PHASE1|PHASE2
RECRUITING
NCT06730347A Study of Lorigerlimab in Participants With Advanced Solid Tumors
MacroGenics
PHASE2
RECRUITING
NCT06748872EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
Medigene AG
PHASE1
NOT_YET_RECRUITING
NCT06751329A Study of DM002 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
PHASE1|PHASE2
RECRUITING
NCT06756035CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
PHASE1
RECRUITING
NCT06760507Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
Emory University
NA
RECRUITING
NCT06760819A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
PHASE2
RECRUITING
NCT06774963A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NextCure, Inc.
PHASE1
RECRUITING
NCT06778863A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics, Inc.
PHASE1
RECRUITING
NCT06787612Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
PHASE2
RECRUITING
NCT06792552A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
PHASE1
RECRUITING
NCT06796907A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
GlaxoSmithKline
PHASE1|PHASE2
RECRUITING
NCT06799065First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Accent Therapeutics
PHASE1|PHASE2
RECRUITING
NCT06815497Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Tyler J Curiel
PHASE2
RECRUITING
NCT06819007Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Daiichi Sankyo
PHASE3
RECRUITING
NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme LLC
PHASE3
RECRUITING
NCT06840886A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
PHASE1
RECRUITING
NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Merck Sharp & Dohme LLC
PHASE1|PHASE2
RECRUITING
NCT06855706An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
Roswell Park Cancer Institute
NA
RECRUITING
NCT06856499Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
PHASE1
RECRUITING
NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
PHASE1
RECRUITING
NCT06887673Lipid Mediators & Cancer: Montelukast, SPM, and Almonds
University of South Florida
EARLY_PHASE1
NOT_YET_RECRUITING
NCT06888921A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Compugen Ltd
PHASE1|PHASE2
ACTIVE_NOT_RECRUITING
NCT06890338A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
PHASE2
RECRUITING
NCT06892275The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
Georgetown University
NA
RECRUITING
NCT06906341Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
PHASE2
RECRUITING
NCT06907043A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Eikon Therapeutics
PHASE1|PHASE2
RECRUITING
NCT06910657IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
PHASE1
RECRUITING
NCT06914726Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
HealthPartners Institute
NA
ENROLLING_BY_INVITATION
NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon
PHASE3
RECRUITING
NCT06930755Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Nerviano Medical Sciences
PHASE1
RECRUITING
NCT06943521A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
PHASE1|PHASE2
RECRUITING
NCT06953089DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
PHASE2
RECRUITING
NCT06964009DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Elizabeth Stover, MD, PhD
PHASE1
RECRUITING
NCT06971744Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
PHASE2
RECRUITING
NCT06979596A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Merck Sharp & Dohme LLC
PHASE2
RECRUITING
NCT06993844Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
PHASE1|PHASE2
RECRUITING
NCT06995898The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
NA
RECRUITING
NCT06997029A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
PHASE1
RECRUITING
NCT06999187A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
PHASE1
RECRUITING
NCT07001592Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
PHASE1
RECRUITING
NCT07001748Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ECOG-ACRIN Cancer Research Group
PHASE2|PHASE3
RECRUITING
NCT07023627A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Incyte Corporation
PHASE2
RECRUITING
NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
PHASE2
RECRUITING
NCT07030283Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
University of Colorado, Denver
PHASE1
RECRUITING
NCT07030907A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Outpace Bio, Inc.
PHASE1
RECRUITING
NCT07050771Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
PHASE2
RECRUITING
NCT07059845A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
AbbVie
PHASE2
RECRUITING
NCT07059884Distance-Based Exercise to Preserve Function and Prevent Disability
Alliance for Clinical Trials in Oncology
NA
RECRUITING
NCT07064018Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
PHASE1|PHASE2
RECRUITING
NCT07078409Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology
Abramson Cancer Center at Penn Medicine
NA
ENROLLING_BY_INVITATION
NCT07084168Multimedia Aid for Genetic Testing in Gynecologic Oncology
UNC Lineberger Comprehensive Cancer Center
NA
RECRUITING
NCT07090109PITCH - Impacting Hereditary Cancer Testing
Rachel Miller
NA
NOT_YET_RECRUITING
NCT07109726A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
PHASE1|PHASE2
RECRUITING
NCT07115043A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
PHASE1|PHASE2
RECRUITING
NCT07144826Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
Ohio State University Comprehensive Cancer Center
EARLY_PHASE1
RECRUITING
NCT07151391The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
PHASE2
RECRUITING
NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
University of Michigan Rogel Cancer Center
PHASE2
RECRUITING
NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo, Inc.
PHASE1
RECRUITING
NCT07186842A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
PHASE1|PHASE2
RECRUITING
NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
PHASE1|PHASE2
RECRUITING
NCT07211659Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Theolytics Limited
PHASE1
RECRUITING
NCT07213791A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
PHASE1
RECRUITING
NCT07213804A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Eli Lilly and Company
PHASE3
RECRUITING
NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Incyte Corporation
PHASE3
RECRUITING
NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
PHASE1
RECRUITING
NCT07218809AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
AstraZeneca
PHASE3
RECRUITING
NCT07219238Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare
PHASE2|PHASE3
RECRUITING
NCT07224464The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase Ltd.
NA
RECRUITING
NCT07225270Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Genmab
PHASE3
RECRUITING
NCT07226427A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Stemline Therapeutics, Inc.
PHASE1
RECRUITING
NCT07229313A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
PHASE1
RECRUITING
NCT07253662Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma
Northwell Health
PHASE1
RECRUITING
NCT07265739Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
PHASE2
NOT_YET_RECRUITING
NCT07278336A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
AbbVie
PHASE1
RECRUITING
NCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
Mayo Clinic
NA
RECRUITING
NCT07282158Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
Fred Hutchinson Cancer Center
NA
RECRUITING
NCT07282834Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
Patrick Wagner, MD, FACS
PHASE2
RECRUITING
NCT07285044The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
PHASE2
RECRUITING
NCT07287098A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Eli Lilly and Company
PHASE2
RECRUITING
NCT07290309Survivors Uniting for Remote Guided Exercise
Colorado State University
NA
RECRUITING
NCT07303894A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
PHASE2
RECRUITING
NCT07306559A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
PHASE1
RECRUITING
NCT07310420A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
TerSera Therapeutics LLC
PHASE1
RECRUITING
NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Merck Sharp & Dohme LLC
PHASE3
RECRUITING
NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL Biotherapeutics, LLC
PHASE1|PHASE2
RECRUITING
NCT07360314Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
PHASE1
RECRUITING
NCT07381985Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment
University of Vermont Medical Center
NA
ENROLLING_BY_INVITATION
NCT07389239A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
University of Chicago
PHASE1|PHASE2
RECRUITING
NCT07406087Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Kaiser Permanente
NA
RECRUITING
NCT07408258Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
OncoC4, Inc.
PHASE1
RECRUITING
NCT07411599Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
M.D. Anderson Cancer Center
PHASE1|PHASE2
RECRUITING
NCT07419490Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy
University of South Florida
NA
RECRUITING
NCT07424547Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
PHASE1
RECRUITING
NCT07432633[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
PHASE1|PHASE2
RECRUITING
NCT07444814Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Whitehawk Therapeutics, Inc.
PHASE1
RECRUITING
NCT07446855Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
AstraZeneca
PHASE1|PHASE2
RECRUITING
NCT07447050Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
PHASE2
RECRUITING
NCT07460752Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Mayo Clinic
PHASE2
RECRUITING
NCT07470853A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Whitehawk Therapeutics, Inc.
PHASE1
RECRUITING
NCT07475286Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis
Mohammad Haroon Asif Choudry
PHASE2
RECRUITING
NCT07487168Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
PHASE1
RECRUITING
NCT07488676A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Astellas Pharma Global Development, Inc.
PHASE1|PHASE2
RECRUITING
NCT07489287GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
PHASE1
RECRUITING
NCT07495124IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
PHASE2
RECRUITING
NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
PHASE1
RECRUITING
NCT07504588Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
National Cancer Institute (NCI)
PHASE2
RECRUITING
NCT07509008Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
M.D. Anderson Cancer Center
PHASE1|PHASE2
RECRUITING
NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
PHASE1
RECRUITING
NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Regor Pharmaceuticals Inc.
PHASE1
RECRUITING
NCT07542405A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families
University of Michigan Rogel Cancer Center
NA
NOT_YET_RECRUITING
NCT07546500A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
PHASE3
RECRUITING
NCT07564141Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Genmab
PHASE3
RECRUITING
NCT07591623OCRA Distress & Unmet Needs
M.D. Anderson Cancer Center
NA
NOT_YET_RECRUITING
NCT07593092Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Xencor, Inc.
PHASE1
RECRUITING
NCT07596212BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
PHASE1|PHASE2
NOT_YET_RECRUITING
NCT07634094Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
Kalinski, Pawel, MD, PhD
PHASE2
NOT_YET_RECRUITING
NCT07636200The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
University of Colorado, Boulder
NA
RECRUITING
NCT07638410Prehabilitation in High-risk Oncologic Surgery
Fox Chase Cancer Center
NA
RECRUITING
NCT07653594TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
Case Comprehensive Cancer Center
NA
NOT_YET_RECRUITING
NCT07658196TLR9 Immunotherapy for Peritoneal Carcinomatosis
Brown University
PHASE1
RECRUITING
NCT07671937INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
University of Alabama at Birmingham
NA
RECRUITING
NCT07690189Study of NTB-928 in R/R OC
TeneoSeven, Inc.
PHASE1
RECRUITING
NCT07705035DBC-664 in Adult Patients With Solid Tumors
Duboce Biopharmaceuticals, Inc.
PHASE1
RECRUITING
NCT07718854Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Tufts Medical Center
PHASE2
RECRUITING
NCT07720180Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
Medical University of South Carolina
PHASE2
NOT_YET_RECRUITING
NCT07736937Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Gilead Sciences
PHASE1|PHASE2
RECRUITING
NCT07741968A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
City of Hope Medical Center
NA
RECRUITING
NCT07749586A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Arvinas Inc.
PHASE1|PHASE2
RECRUITING
NCT07755436Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
ArriVent BioPharma, Inc.
PHASE1
RECRUITING
NCT07764744Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
Weill Medical College of Cornell University
NA
NOT_YET_RECRUITING
NCT07772869Uterine Lavage to Detect Ovarian Cancer Risk
University of Washington
NA
RECRUITING
NCT07772882Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Rebecca Arend
PHASE1
NOT_YET_RECRUITING
NCT07776691A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Merck Sharp & Dohme LLC
PHASE3
RECRUITING
NCT07781852Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
Lumina Pharmaceuticals Inc
EARLY_PHASE1
NOT_YET_RECRUITING
NCT07795749Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)
University of California, Irvine
PHASE2
RECRUITING
NCT07811297A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
Advenchen Pharmaceuticals, LLC.
PHASE1|PHASE2
NOT_YET_RECRUITING
NCT07814248A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
TwoStep Therapeutics, Inc.
PHASE1
RECRUITING
NCT07815704Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin
University of Colorado, Denver
PHASE2
NOT_YET_RECRUITING
NCT07816666Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
AstraZeneca
PHASE3
RECRUITING
NCT07824960Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma
University of Virginia
PHASE1|PHASE2
NOT_YET_RECRUITING
NCT07851025Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
AstraZeneca
PHASE3
RECRUITING